Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria

被引:24
作者
De Serres, Sacha A. [1 ]
Isenring, Paul [1 ]
机构
[1] Univ Laval, Fac Med, Dept Med, Nephrol Res Grp,Hotel Dieu Quebec Res Inst, Quebec City, PQ G1K 7P4, Canada
关键词
haemolytic uraemic syndrome; plasmapheresis; renal failure; serum LDH; thrombotic microangiopathies; HEMOLYTIC-UREMIC SYNDROME; THROMBOCYTOPENIC PURPURA;
D O I
10.1093/ndt/gfn687
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
Background. Thrombotic thrombocytopenic purpura (TTP) and haemolytic uraemic syndrome (HUS) are thrombotic microangiopathies (TMAs). They are generally diagnosed and treated by plasmapheresis in the presence of non-immune haemolytic anaemia and thrombocytopenia. Yet, many individuals admitted in our hospital for athrombocytopenic renal failure of unknown cause were reported to have TMA as main lesion on kidney biopsies. Methods. Speculating that this presentation is not uncommon and that the underlying lesion might not be suspected because of current diagnostic criteria, we determined its prevalence and other accompanying features through a retrospective single-centre cohort of 50 cases where TMA had been identified histologically. Results. At presentation, normal serum platelets were common (44%) but still accompanied by abnormal serum LDH in most subjects. End-stage renal disease and mortality at 5 years were also high especially in the athrombocytopenic group, but unrelated to the underlying aetiology of TMA. Importantly, several subjects in both groups received and apparently responded to plasmapheresis. Conclusion. In the absence of thrombocytopenia, TMA should still be contemplated when renal failure is associated with high serum LDH and its possible treatment with plasmapheresis assessed through prospective trials.
引用
收藏
页码:1048 / 1050
页数:3
相关论文
共 16 条
[1]
THROMBOTIC THROMBOCYTOPENIC PURPURA - REPORT OF 16 CASES AND REVIEW OF LITERATURE [J].
AMOROSI, EL ;
ULTMANN, JE .
MEDICINE, 1966, 45 (02) :139-+
[2]
IMPROVED SURVIVAL IN THROMBOTIC THROMBOCYTOPENIC PURPURA HEMOLYTIC UREMIC SYNDROME - CLINICAL-EXPERIENCE IN 108 PATIENTS [J].
BELL, WR ;
BRAINE, HG ;
NESS, PM ;
KICKLER, TS .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (06) :398-403
[3]
Thrombotic microangiopathies: An update [J].
Franchini, Massimo .
HEMATOLOGY, 2006, 11 (03) :139-146
[4]
GASSER C, 1955, Schweiz Med Wochenschr, V85, P905
[5]
Thrombotic thrombocytopenic purpura [J].
George, JN .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (18) :1927-1935
[6]
George JN, 1998, J CLIN APHERESIS, V13, P120, DOI 10.1002/(SICI)1098-1101(1998)13:3<120::AID-JCA5>3.0.CO
[7]
2-E
[8]
Where next with atypical hemolytic uremic syndrome? [J].
Jokiranta, T. Sakari ;
Zipfel, Peter F. ;
Fremeaux-Bacchi, Veronique ;
Taylor, C. Mark ;
Goodship, Timothy J. H. ;
Noris, Marina .
MOLECULAR IMMUNOLOGY, 2007, 44 (16) :3889-3900
[9]
Pathogenesis and prognosis of thrombotic microangiopathy [J].
Nangaku M. ;
Nishi H. ;
Fujita T. .
Clinical and Experimental Nephrology, 2007, 11 (2) :107-114
[10]
COMPARISON OF PLASMA-EXCHANGE WITH PLASMA INFUSION IN THE TREATMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA [J].
ROCK, GA ;
SHUMAK, KH ;
BUSKARD, NA ;
BLANCHETTE, VS ;
KELTON, JG ;
NAIR, RC ;
SPASOFF, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (06) :393-397